Cardiac abnormalities in acromegaly: Pathophysiology and implications for management

Treatments in Endocrinology

Volumn 3, Issue 5, 2004, Pages 309-318

  Vitale, Giovanni ^a   Pivonello, Rosario ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CARDIOMYOPATHY; DIABETES MELLITUS; EARLY DIAGNOSIS; HEART ARRHYTHMIA; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART RATE; HUMAN; HYPERKINESIA; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ACROMEGALY; HEART DISEASES; HUMANS;

EID: 4644304160     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403050-00004     Document Type: Review

References (136)

1. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995; 30: 825-34
2. Toyozaki T, Hiroe M, Hasumi M, et al. Insulin like growth factor I receptors in human cardiac myocytes and their relation to myocardial hypertrophy. Jpn Circ J 1993; 57: 1120-7
3. Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol 2001; 54: 137-54
4. Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86: 293-9
5. Bengtsson BA, Bergh CH, Caidahl K, et al. An overview of cardiac function and implication for growth hormone: cardiomyopathy. J Endocrinol Invest 1998; 21: 80-3
6. Nabarro JD. Acromegaly. Clin Endocrinol 1987; 26: 481-512
7. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-4
8. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994; 41: 95-102
9. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555-73
10. Wright AD, Hill DM, Lowy C, et al. Mortality in acromegaly. Q J Med 1970; 39; 1-16
11. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004; 25 (1): 102-52
12. Colao A, Cuocolo A, Di Somma C, et al. Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. Clin Endocrinol 2000; 52: 447-55
13. Cuocolo A, Nicolai E, Colao A, et al. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography. Eur J Nucl Med 1996; 23: 390-4
14. Diez J, Insulin-like growth factor I in essential hypertension. Kidney Int 1999; 55: 744-59
15. Hanson MC, Kenneth AF, Alexander RV, et al. Induction of cardiac insulin-like growth factor-I gene expression in pressure overload hypertrophy. Am J Med Sci 1993; 306: 69-74
16. Isgaard J, Wahlander H, Adams MA, et al. Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume-overloaded hearts. Hypertension 1994; 23: 884-8
17. Reiss K, Meggs LG, Li P, et al. Upregulation of IGF-I, IGF-I receptor and late growth-related genes in ventricular myocytes after infarction in rats. J Cell Physiol 1994; 158: 160-8
18. Wahlander H, Isgaard J, Jennische E, et al. Left ventricular insulin-like growth factor-I increases in early renal hypertension. Hypertension 1992; 19: 25-32
19. Guron G, Friberg P, Wickman A, et al. Cardiac insulin-like growth factor I and growth hormone receptor expression in renal hypertension. Hypertension 1996; 27: 636-42
20. Isgaard J, Tivesten A, Friberg P, et al. The role of the GH/IGF-I axis for cardiac function and structure. Horm Metab Res 1999; 31: 50-4
21. Courville C, Mason VR. The heart in acromegaly. Arch Intern Med 1938; 61: 704-13
22. Hunter JJ, Chien KR. Signalling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341: 1276-83
23. Cittadini A, Stromer H, Katz SE, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat: a combined in vivo and in vitro evaluation. Circulation 1996; 93: 800-9
24. Cittadini A, Ishiguro Y, Strömer H, et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ Res 1998; 83: 50-9
25. Freestone NS, Ribaric S, Mason WT, et al. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol Cell Biochem 1996; 163: 223-9
26. Xu XP, Best PM. Decreased transient outward K+ current in ventricular myocytes from acromegalic rats. Am J Physiol 1991; 260 (3 Pt 2): H935-42
27. Rubin SA, Buttrick P, Malhotra A, et al. Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat. J Mol Cell Cardiol 1990; 22: 429-38
28. Ito H, Hiroe M, Hirata Y, et al. Insulin like growth factor 1 induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715-21
29. Hejtmancik MR, Bradfield JY, Herrmann GR. Acromegaly and the heart: a clinical and pathologic study. Ann Intern Med 1951; 34: 1445-56
30. Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 1980; 100: 41-4
31. Hay ward RP, Emanuel RW, Nabarro JDN. Acromegalic heart disease: influence of treatment of the acromegaly on the heart. Q J Med 1987; 62: 41-5
32. Frustaci A, Cimenti C, Setoguchi M, et al. Cell death in acromegalic cardiomyopathy. Circulation 1999; 99: 1426-34
33. Colao A. Are patients with acromegaly at risk for dysrhythmias? Clin Endocrinol 2001; 55: 305-6
34. Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J 1992; 3: 51-5
35. Ho KY, Kelly JJ. Role of growth hormone in fluid homeostasis. Horm Res 1991; 36: 44-8
36. Hansen TK, Moller J, Thomsen K, et al. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 2001; 281: E1326-32
37. Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 1996; 17: 423-80
38. Moller J, Jorgensen JO, Marqversen J, et al. Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor. Clin Endocrinol 2000; 52 (2): 181-6
39. Ikeda T, Terasawa H, Ishimura M, et al. Correlation between blood pressure and plasma insulin in acromegaly. J Intern Med 1993; 234: 61-3
40. Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, et al. High blood pressure and hyperinsulinaemia in acromegaly and in obesity. Clin Exp Hypertens A 1989; 11: 407-25
41. Sonksen PH, Greenwood FC, Ellis JP, et al. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab 1967; 27: 1418-30
42. Melmed S, Ho K, Klibanski A, et al. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1996; 80: 3395-402
43. Arosio M, Macchelli S, Rossi CM, et al. Effects of treatment with octreotide in acromegalic patients: a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995; 133: 430-9
44. Biering H, Knappe G, Gerl H, et al. Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 2000; 27: 27-31
45. Nikkila EA, Pelkonen R. Serum lipids in acromegaly. Metabolism 1975; 24: 829-38
46. Takeda R, Tatami R, Ueda K, et al. The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients. Acta Endocrinol (Copenh) 1982; 100: 358-62
47. Tan KC, Shiu SW, Janus ED, et al. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 1997; 129: 59-65
48. Maffei P, Sicolo N, Plebani M. Lipoprotein(a) in acromegaly. Ann Intern Med 1999; 130: 537-8
49. Maldonado Castro GF, Escobar-Morreale HF, et al. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clin Endocrinol (Oxf) 2000; 53: 313-9
50. Arosio M, Sartore G, Rossi CM, et al. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients: effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000; 151: 551-7
51. Hainer V, Zak A, Sindelkova E, et al. Elevation of high density lipoproteins in acromegalics after lisuride treatment. Horm Metab Res 1985; 17: 220-1
52. Kamide K, Hori MT, Zhu JH, et al. Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000; 18: 1051-6
53. Standley PR, Stanley MA, Senechal P, et al. Activation of mitogenic and antimitogenic pathways in cyclically stretched arterial smooth muscle. Am J Physiol Endocrinol Metab 2001; 281: E1165-71
54. Chen Y, Capron L, Magnusson JO, et al. Insulin-like growth factor-1 stimulates vascular smooth muscle cell proliferation in rat aorta in vivo. Growth Horm IGF Res 1998; 8 (4): 299-303
55. Bruel A, Oxlund H. Biosynthetic growth hormone increases the collagen deposition rate in rat aorta and heart. Eur J Endocrinol 1995; 132: 195-9
56. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997; 29: 691-9
57. Evans LM, Davies JS, Goodfellow J, et al. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol 1999; 50: 457-64
58. McGuffin Jr WL, Sherman BM, Roth J, et al. Acromegaly and cardiovascular disorders: a prospective study. Ann Intern Med 1974; 81: 11-8
59. Fazio S, Cittadini A, Sabatini D, et al. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Heart J 1993; 14: 26-33
60. Levy D, Savage DD, Garrison RJ, et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 59: 956-61
61. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass: anatomic validation of the method. Circulation 1977; 55: 613-7
62. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on standards, subcommittee on quantification of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-62
63. de Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20 (5): 1251-6
64. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography: anatomic validation, standardization and comparison to other methods. Hypertension 1987; 9: 19-25
65. Vitale G, Galderisi M, Pivonello R, et al. Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass. Clin Endocrinol (Oxf) 2004 Mar; 60 (3): 343-9
66. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000; 85: 193-9
67. Colao A, Merola B, Ferone D, et al. Extensive personal experience: acromegaly. J Clin Endocrinol Metab 1997; 82: 2777-81
68. Minniti G, Jaffrain-Rea ML, Moroni C, et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol (Oxf) 1998; 49: 101-6
69. Fazio S, Cittadini A, Biondi B, et al. Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab 2000; 85: 179-82
70. Mercuro H, Zonco S, Colonna P, et al. Cardiac dysfunction in acromegaly: evidence by pulsed wave tissue Doppler imaging. Eur J Endocrinol 2000; 143: 363-9
71. Herrmann BL, Bruch C, Saller B, et al. Acromegaly: evidence for a direct relation between cardiac dysfunction in patients without ventricular hypertrophy. Clin Endocrinol (Oxf) 2002; 56: 595-602
72. Bruch C, Herrmann BL, Schmermund A, et al. Impact of disease activity on left ventricular performance in patients with agromegaly. Am Heart J 2002; 144: 538-43
73. Bonow RO, Bacharach SL, Green MV, et al. Impaired left ventricular diastolic filling in patients with coronary artery disease: assessment with radionuclide angiography. Circulation 1981; 64: 315-23
74. Bonow RO, Vitale DF, Bacharach SL, et al. Asynchronous left ventricular regional function and impaired global diastolic filling in patients with coronary artery disease: reversal after coronary angioplasty. Circulation 1985; 71: 297-307
75. Bonow RO, Vitale DF, Bacharach SL, et al. Effects of aging on asynchronous left ventricular regional function and global ventricular filling in normal human subjects. J Am Coll Cardiol 1988; 11: 50-8
76. Cuocolo A, Nicolai E, Fazio S, et al. Impaired left ventricular diastolic filling in patients with acromegaly: assessment with radionuclide angiography. J Nucl Med 1995; 36: 196-201
77. Fazio S, Cittadini A, Cuocolo A, et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab 1994; 79: 441-6
78. Colao A, Cuocolo A, Marzullo P, et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab 1999; 84: 1518-23
79. Lombardi G, Colao A, Marzullo P, et al. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J Endocrinol 1997; 155: S33-7
80. Zlatareva N, Andreeva M, Angelova I. Echocardiographic evaluation of left ventricular function in acromegaly patients [abstract]. Endocrinologia (J Bulgarian Soc Endocrinol) 2000; 5: 3
81. Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 2003; 88: 3196-201
82. Surawicz B, Mangiardi ML. Electrocardiogram in endocrine and metabolic disorders. Cardiovasc Clin 1977; 8: 243-7
83. Rodrigues EA, Caruana MP, Lahiri A, et al. Subclinical cardiac dysfunction in acromegaly evidence for a specific disease of heart muscle. Br Heart J 1989; 62: 185-9
84. Herrmann BL, Bruch C, Saller B, et al. Occurrence of left ventricular late potentials in patients with active acromegaly. Clin Endocrinol 2001; 55: 201-7
85. Lopez-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997; 82: 1047-53
86. Jaffrain-Rea ML, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 2001; 54: 189-95
87. Pietrobelli DJ, Akopian M, Olivieri AO, et al. Altered circadian blood pressure profile in patients with active acromegaly: relationship with left ventricular mass and hormonal values. J Hum Hypertens 2001; 15: 601-5
88. Fukuda I, Hizuka N, Murakami Y, et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med 2001; 40: 987-92
89. Minniti G, Moroni C, Jaffrain-Rea ML, et al. Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring. Clin Endocrinol (Oxf) 1998; 48: 149-52
90. Ohtsuka H, Komiya I, Aizawa T, et al. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocr J 1995; 42: 781-7
91. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly: clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73: 233-40
92. Kraatz C, Benker G, Weber F, et al. Acromegaly and hypertension: prevalence and relationship to the renin-angiotensin-aldosterone system. Klin Wochenschr 1990; 19: 583-7
93. Otsuki M, Kasayama S, Yamamoto H, et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol (Oxf) 2001; 54: 791-6
94. Terzolo M, Matrella C, Boccuzzi A, et al. Twenty-four hour profile of blood pressure in patients with acromegaly: correlation with demographic, clinical and hormonal features. J Endocrinol Invest 1999; 22: 48-54
95. Harrison BD, Millhouse KA, Harrington M, et al. Lung function in acromegaly. Q J Med 1978; 47: 517-21
96. Herrmann BL, Brandt-Mainz K, Saller B, et al. Myocardial perfusion abnormalities in patients with active acromegaly. Horm Metab Res 2003; 35: 183-8
97. Colao A, Spiezia S, Cerbone G, et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 2001; 54: 515-24
98. Maison P, Demolis P, Young J, et al. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf) 2000; 53: 445-51
99. Brevetti G, Marzullo P, Silvestro A, et al. Early vascular alterations in acromegaly. J Clin Endocrinol Metab 2002; 87: 3174-9
100. Swearingen B, Barker FGII, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3419-26
101. Ferone D, Colao A, van der Lely AJ, et al. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs 2000; 17: 81-92
102. Baldwin A, Cundy T, Butler J, et al. Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Acta Endocrinol (Copenh) 1985 Jan; 108 (1): 26-30
103. Abs R, Versholst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83: 374-8
104. Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997; 82: 518-23
105. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 1998; 139: 516-21
106. Luboshitzky R, Barzilai D. Bromocriptine for an acromegalic patient: improvement in cardiac function and carpal tunnel syndrome. JAMA 1980; 244: 1825-7
107. Thuesen L, Christensen SE, Weeke J, et al. The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol 1989; 30: 619-25
108. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990; 113: 921-5
109. Pereira J, Rodriguez-Puras MJ, Leal-Cerro A, et al. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 1991; 14: 17-23
110. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992; 117: 719-26
111. Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993; 77: 790-3
112. Tokgözoglu SL, Erbas T, Aytemir K, et al. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 1994; 74: 1072-4
113. Colao A, Cuocolo A, Marzullo P, et al. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999; 84: 17-23
114. Baldelli R, Ferretti E, Jaffrain-Rea ML, et al. Cardiac effects of lanreotide, a slow release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999; 84 (2): 527-32
115. Hradec J, Kral J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 1999; 83: 1506-9
116. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR® in acromegaly. J Clin Endocrinol Metab 2000; 86: 3132-40
117. Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002; 87: 3097-104
118. Lombardi G, Colao A, Marzullo P, et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly: a prospective multi-center study. J Endocrinol Invest 2002; 25: 971-6
119. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 2003; 58: 169-76
120. Lamberts SWJ, van der Lely A-J, de Herder WW, et al. Octreotide. N Engl J Med 1996; 334: 246-54
121. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 2001; 86: 1551-7
122. Chanson P, Timsit J, Masquet C, et al. Heart failure responsive to octreotide in patient with acromegaly. Lancet 199; I: 1263-4
123. Giustina A, Boni E, Romanelli G, et al. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 1995; 75: 1042-7
124. Caron P, Morange-Ramos I, Cogne M, et al. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82: 18-22
125. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998; 352: 1455-61
126. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR): a review of its phamacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53: 681-99
127. Lancranjan I, Atkinson AB. Results of a European multicentre study with sandostatin LAR in acromegalic patients. Pituitary 1999; 1: 105-14
128. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342: 1171-7
129. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754-9
130. Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002; 12: 418-24
131. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization cf serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002; 87: 1692-9
132. Vitale G, Pivonello R, Galderisi M, et al. Cardiovascular complications in acromegaly: methods of assessment. Pituitaiy 2001; 4: 251-7
133. Gomberg-Maitland M, Frishman WH. Thyroid hormone and cardiovascular disease. Am Heart J 1998; 135: 187-96
134. Bennett N, Gabrielli A, Chernow B. Hypotension and adrenal insufficiency. J Clin Anesthesiol 1999; 11: 425-30
135. Dorin RI, Kearns PJ. High output circulatory failure in acute adrenal insufficiency. Critl Care Med 1988; 16: 296-7
136. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003; 24: 272-7